Nutra Pharma Corp Financials
This page shows Nutra Pharma Corp (NPHC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny revenue, persistent cash burn, and a liability-heavy balance sheet leave this business operating mainly on financing inflows.
From FY2023 to FY2025, revenue increased by only$52K while operating cash outflow worsened to-$1.16M . At the same time, financing inflows reached$1.19M , revealing a funding model in which fresh capital is replacing internally generated cash rather than merely supporting expansion.
FY2025 ended with just
Overhead trimming is visible: selling, general and administrative expense fell from
Financial Health Signals
We are recalculating Nutra Pharma Corp's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Nutra Pharma Corp scores -229.73, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1M) relative to total liabilities ($17.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nutra Pharma Corp passes 6 of 9 financial strength tests. 1 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Nutra Pharma Corp generates $0.57 in operating cash flow (-$1.2M OCF vs -$2.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Nutra Pharma Corp earns $-63.9 in operating income for every $1 of interest expense (-$1.5M vs $23K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Nutra Pharma Corp generated $258K in revenue in fiscal year 2025. This represents an increase of 4.6% from the prior year.
Nutra Pharma Corp's EBITDA was -$1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 66.7% from the prior year.
Nutra Pharma Corp reported -$2.0M in net income in fiscal year 2025. This represents a decrease of 59.2% from the prior year.
Cash & Balance Sheet
Nutra Pharma Corp generated -$1.2M in free cash flow in fiscal year 2025, representing cash available after capex.
Nutra Pharma Corp held $12K in cash against $137K in long-term debt as of fiscal year 2025.
Nutra Pharma Corp had 7.10B shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Nutra Pharma Corp's gross margin was 76.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.8 percentage points from the prior year.
Nutra Pharma Corp's operating margin was -567.6% in fiscal year 2025, reflecting core business profitability. This is down 211.0 percentage points from the prior year.
Nutra Pharma Corp's net profit margin was -794.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 272.8 percentage points from the prior year.
Capital Allocation
Nutra Pharma Corp invested $26K in capex in fiscal year 2025, funding long-term assets and infrastructure.
NPHC Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27K-5.6% | $29K-58.9% | $70K-16.9% | $85K+14.3% | $74K-9.6% | $82K+9.2% | $75K+45.0% | $52K |
| Cost of Revenue | $29K-48.5% | $57K+66.4% | $34K-26.6% | $47K+0.5% | $46K+132.0% | $20K-16.1% | $24K+27.7% | $19K |
| Gross Profit | -$2K+26.4% | -$3K-104.2% | $65K-14.6% | $76K+27.9% | $59K+162.7% | $23K-68.2% | $71K+113.7% | $33K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $170K+133.8% | -$504K-219.8% | $421K+14.9% | $366K-12.4% | $418K+57.5% | $265K+3.9% | $255K-6.9% | $274K |
| Operating Income | -$379K+18.6% | -$466K-30.8% | -$356K-22.6% | -$291K+16.9% | -$350K-95.6% | -$179K+3.2% | -$185K+15.8% | -$219K |
| Interest Expense | $6K+0.8% | $6K+3.0% | $6K+4.1% | $6K-0.6% | $6K+0.1% | $6K+3.0% | $5K+4.1% | $5K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$460K+5.9% | -$489K+6.7% | -$524K-241.7% | $370K+126.3% | -$1.4M-508.4% | -$231K+11.4% | -$261K+29.0% | -$367K |
| EPS (Diluted) | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 |
NPHC Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $617K+5.5% | $585K-17.7% | $710K-17.4% | $859K+10.8% | $775K+29.3% | $599K+7.3% | $559K-11.4% | $631K |
| Current Assets | $499K+8.7% | $460K-15.7% | $545K-18.0% | $665K+20.5% | $552K+47.3% | $375K+20.6% | $311K-13.7% | $360K |
| Cash & Equivalents | $22K+79.3% | $12K+238.1% | $4K-95.4% | $79K+471.2% | $14K-62.0% | $36K | $0 | $0 |
| Inventory | $24K+20.3% | $20K+11.5% | $18K+11.9% | $16K-10.9% | $18K-0.7% | $18K+3.6% | $17K-28.1% | $24K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $23K+2.5% | $23K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $17.9M+2.7% | $17.4M+2.0% | $17.1M+2.2% | $16.7M-1.7% | $17.0M+10.3% | $15.4M+0.2% | $15.4M+1.2% | $15.2M |
| Current Liabilities | $17.7M+2.7% | $17.3M+2.1% | $16.9M+2.2% | $16.6M-1.7% | $16.8M+10.4% | $15.3M+0.4% | $15.2M+1.4% | $15.0M |
| Long-Term Debt | $136K-0.7% | $137K-0.7% | $138K-0.6% | $138K-0.6% | $139K-0.6% | $140K-0.6% | $141K-0.6% | $142K |
| Total Equity | -$17.3M-2.6% | -$16.8M-2.9% | -$16.4M-3.3% | -$15.8M+2.3% | -$16.2M-9.5% | -$14.8M+0.1% | -$14.8M-1.8% | -$14.6M |
| Retained Earnings | -$78.7M-0.6% | -$78.3M-0.6% | -$77.8M-0.7% | -$77.3M+0.5% | -$77.6M-1.8% | -$76.2M-0.3% | -$76.0M-0.3% | -$75.7M |
NPHC Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$328K-49.1% | -$220K+12.3% | -$251K+13.0% | -$288K+28.8% | -$405K-127.3% | -$178K-1034.4% | $19K+120.4% | -$94K |
| Capital Expenditures | N/A | $0 | $0 | $0-100.0% | $26K | N/A | N/A | N/A |
| Free Cash Flow | N/A | -$220K+12.3% | -$251K+13.0% | -$288K+33.1% | -$431K | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0 | $0+100.0% | -$25K+4.0% | -$26K-413.9% | $8K-75.6% | $34K | N/A |
| Financing Cash Flow | $337K+47.7% | $228K+30.3% | $175K-53.7% | $379K-7.3% | $408K+97.9% | $206K+488.8% | -$53K-156.1% | $95K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NPHC Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -7.3%+2.1pp | -9.4%-101.3pp | 91.9%+2.5pp | 89.5%+9.5pp | 79.9%+52.4pp | 27.5%-66.8pp | 94.3%+30.3pp | 64.0% |
| Operating Margin | -1391.9%+222.2pp | -1614.2%-1107.2pp | -506.9%-163.2pp | -343.7%+129.2pp | -472.9%-254.4pp | -218.5%+27.9pp | -246.4%+178.1pp | -424.5% |
| Net Margin | -1687.1%+5.4pp | -1692.5%-947.2pp | -745.3%-1182.5pp | 437.2%+2336.4pp | -1899.2%-1617.2pp | -282.0%+65.6pp | -347.6%+362.4pp | -710.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -74.6%+9.0pp | -83.6%-9.8pp | -73.8%-116.8pp | 43.0%+224.3pp | -181.2%-142.7pp | -38.5%+8.1pp | -46.7%+11.5pp | -58.2% |
| Current Ratio | 0.030.0 | 0.030.0 | 0.030.0 | 0.040.0 | 0.030.0 | 0.020.0 | 0.020.0 | 0.02 |
| Debt-to-Equity | -0.010.0 | -0.010.0 | -0.010.0 | -0.010.0 | -0.010.0 | -0.010.0 | -0.010.0 | -0.01 |
| FCF Margin | N/A | -761.6%-404.5pp | -357.0%-15.9pp | -341.1%+241.6pp | -582.7% | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$16.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Nutra Pharma Corp's annual revenue?
Nutra Pharma Corp (NPHC) reported $258K in total revenue for fiscal year 2025. This represents a 4.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nutra Pharma Corp's revenue growing?
Nutra Pharma Corp (NPHC) revenue grew by 4.6% year-over-year, from $246K to $258K in fiscal year 2025.
Is Nutra Pharma Corp profitable?
No, Nutra Pharma Corp (NPHC) reported a net income of -$2.0M in fiscal year 2025, with a net profit margin of -794.8%.
What is Nutra Pharma Corp's EBITDA?
Nutra Pharma Corp (NPHC) had EBITDA of -$1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Nutra Pharma Corp have?
As of fiscal year 2025, Nutra Pharma Corp (NPHC) had $12K in cash and equivalents against $137K in long-term debt.
What is Nutra Pharma Corp's gross margin?
Nutra Pharma Corp (NPHC) had a gross margin of 76.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nutra Pharma Corp's operating margin?
Nutra Pharma Corp (NPHC) had an operating margin of -567.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nutra Pharma Corp's net profit margin?
Nutra Pharma Corp (NPHC) had a net profit margin of -794.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nutra Pharma Corp's free cash flow?
Nutra Pharma Corp (NPHC) generated -$1.2M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nutra Pharma Corp's operating cash flow?
Nutra Pharma Corp (NPHC) generated -$1.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nutra Pharma Corp's total assets?
Nutra Pharma Corp (NPHC) had $585K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nutra Pharma Corp's capital expenditures?
Nutra Pharma Corp (NPHC) invested $26K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Nutra Pharma Corp's current ratio?
Nutra Pharma Corp (NPHC) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Nutra Pharma Corp's debt-to-equity ratio?
Nutra Pharma Corp (NPHC) had a debt-to-equity ratio of -0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nutra Pharma Corp's return on assets (ROA)?
Nutra Pharma Corp (NPHC) had a return on assets of -350.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nutra Pharma Corp's cash runway?
Based on fiscal year 2025 data, Nutra Pharma Corp (NPHC) had $12K in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nutra Pharma Corp's debt-to-equity ratio negative or unusual?
Nutra Pharma Corp (NPHC) has negative shareholder equity of -$16.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nutra Pharma Corp's Altman Z-Score?
Nutra Pharma Corp (NPHC) has an Altman Z-Score of -229.73, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nutra Pharma Corp's Piotroski F-Score?
Nutra Pharma Corp (NPHC) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nutra Pharma Corp's earnings high quality?
Nutra Pharma Corp (NPHC) has an earnings quality ratio of 0.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nutra Pharma Corp cover its interest payments?
Nutra Pharma Corp (NPHC) has an interest coverage ratio of -63.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.